4.7 Article

Bifidobacterium spp. and their metabolite lactate protect against acute pancreatitis via inhibition of pancreatic and systemic inflammatory responses

Journal

GUT MICROBES
Volume 14, Issue 1, Pages -

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1080/19490976.2022.2127456

Keywords

Bifidobacterium; microbial metabolite; lactate; macrophages; pancreatic and systemic inflammation; immunomodulation

Funding

  1. Ten thousand plan innovation leader of Zhejiang Province [2020R52007]
  2. National Natural Science Foundation of China [U21A20261, 82002073, 3217864]

Ask authors/readers for more resources

This study shows that Bifidobacteria, particularly B. animalis, can protect against acute pancreatitis by regulating pancreatic and systemic inflammation. The metabolite lactate produced by B. animalis relieves inflammation through the TLR4/MyD88 and NLRP3/Caspase1 pathways. Clinical research also found a decreased abundance of Bifidobacteria in the intestines of acute pancreatitis patients, which was inversely correlated with the severity of systemic inflammatory responses.
Severe acute pancreatitis (SAP) is a critical illness characterized by a severe systemic inflammatory response resulting in persistent multiple organ failure and sepsis. The intestinal microbiome is increasingly appreciated to play a crucial role in modulation of AP disease outcome, but limited information is available about the identity and mechanism of action for specific commensal bacteria involved in AP-associated inflammation. Here we show that Bifidobacteria, particularly B. animalis, can protect against AP by regulating pancreatic and systemic inflammation in germ-free (GF) and oral antibiotic-treated (Abx) mouse models. Colonization by B. animalis and administration of its metabolite lactate protected Abx and GF mice from AP by reducing serum amylase concentration, ameliorating pancreatic lesions and improving survival rate after retrograde injection of sodium taurocholate. B. animalis relieved macrophage-associated local and systemic inflammation of AP in a TLR4/MyD88- and NLRP3/Caspase1-dependent manner through its metabolite lactate. Supporting our findings from the mouse study, clinical AP patients exhibited a decreased fecal abundance of Bifidobacteria that was inversely correlated with the severity of systemic inflammatory responses. These results may shed light on the heterogeneity of clinical outcomes and drive the development of more efficacious therapeutic interventions for AP, and potentially for other inflammatory disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available